Advertisement
Advertisement

JSPR

JSPR logo

Jasper Therapeutics, Inc. Common Stock

0.80
USD
Sponsored
+0.09
+12.67%
Aug 10, 15:59 UTC -4
Closed
exchange

After-Market

0.78

-0.02
-2.80%

JSPR Earnings Reports

Positive Surprise Ratio

JSPR beat 11 of 19 last estimates.

58%

Next Report

Tomorrow BMO
Date of Next Report
Aug 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$0.35
Implied change from Q1 26 (Revenue/ EPS)
--
/
+775.00%
Implied change from Q2 25 (Revenue/ EPS)
--
/
-79.89%

Jasper Therapeutics, Inc. Common Stock earnings per share and revenue

On May 14, 2026, JSPR reported earnings of -0.04 USD per share (EPS) for Q1 26, beating the estimate of -0.49 USD, resulting in a 91.94% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.72% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of -0.35 USD, with revenue projected to reach -- USD, implying an increase of 775.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Passage Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$2.69
Actual
-$2.44
Surprise
+9.62%
logo
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
logo
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
logo
Biohaven Ltd.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.74
Actual
-$0.91
Surprise
-21.67%
logo
Septerna, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.28
Surprise
+33.26%
logo
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
logo
Sana Biotechnology, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+12.58%
logo
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
logo
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-
Surprise
-
logo
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
FAQ
For Q1 2026, Jasper Therapeutics, Inc. Common Stock reported EPS of -$0.04, beating estimates by 91.94%, and revenue of $0.00, 0% as expectations.
The stock price moved up 1.72%, changed from $0.93 before the earnings release to $0.94 the day after.
The next earning report is scheduled for Aug 11, 2026.
Based on 5 analysts, Jasper Therapeutics, Inc. Common Stock is expected to report EPS of -$0.35 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement